Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery
platforms, continues to progress the development and patenting of its
DehydraTECH(TM) platform. An article discussing the company reads, “The
DehydraTECH(TM) drug-delivery platform can be used to deliver substances in
edible or in beverage form, and in capsules, pills, syrups and more. Brands in
both Canada and the United States have licensed DehydraTECH to make their CBD
and cannabis beverages best-in-class. . . . Not only is ingestion a much safer
form of drug delivery, but DehydraTECH also delivers the active ingredient of
the substance at a rate that is up to five to ten times faster compared with
traditional edible products. A 2018 European clinical study demonstrated that
317% more CBD was delivered within half an hour when compared with a positive
control of equal strength (http://ibn.fm/pXIxY).
The substance being delivered is also rapidly absorbed, which means that people
can achieve the effect they are looking for more quickly than was previously
the case with edibles. For people looking for quick relief of pain, DehydraTECH
is a blessing.”
To view the full article, visit http://ibn.fm/KVdv3
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bioabsorption, reduces time of onset and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products, as well as to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed, in-house research laboratory
and holds a robust intellectual property portfolio with 16 patents granted and
over 60 patents pending worldwide. For more information, visit the company’s
website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
